Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

BERKOWITZ, LAUREEN

NPI: 1104110030 · PROVIDENCE, RI 02904 · Physician Assistant · NPI assigned 06/08/2011

$233K
Total Medicaid Paid
3,449
Total Claims
2,660
Beneficiaries
15
Codes Billed
2018-03
First Month
2024-04
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 528 $40K
2019 158 $11K
2020 777 $44K
2021 1,283 $64K
2022 115 $9K
2023 436 $52K
2024 152 $13K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 891 764 $59K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 569 426 $37K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 111 93 $37K
99215 Prolong outpt/office vis 291 217 $22K
90833 Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) 772 514 $16K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 145 118 $16K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 90 60 $14K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 88 61 $13K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 131 106 $11K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 67 61 $3K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward 36 33 $3K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 69 66 $2K
86780 34 32 $981.77
80305 141 96 $838.00
36415 Collection of venous blood by venipuncture 14 13 $92.85